Relatively high response rates ranging from 40% to 62% were observed in cancers with higher immunogenicity, including Hodgkin lymphoma, Merkel cell cancer (MCC) and cutaneous cancer (CC), microsatellite unstable and/or mismatch repair‐deficient cancers including strong PD‐L1 expressing non‐small‐cell lung cancer (NSCLC).15, 16. Here, CD274 is linked to cancer.